Therapies & Progress

Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C.

Esperion’s portfolio includes one product candidate in global Phase 3 clinical development, Bempedoic Acid (ETC-1002).

Esperion owns the exclusive worldwide rights to bempedoic acid.

 

Esperion Portfolio

 esperion-portfolio-nov-2016_v2